

Hester Pharmaceuticals Limited Regd. Off. : Vilage : Merda-Adraj, Ta : Kadi , Dist : Mehsana, Gujarat - 382 721 UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR QUARTER ENDED 30th SEPTEMBER,2004 Rs.In Lacs						
Sr.No.	Particulars	Quarter Ended on (Unaudited)		Six Month's Ended on (Unaudited)		Year Ended (Audited)
		30.09.2004	30.09.2003	30.09.2004	30.09.2003	31.03.2004
1	Net Income from Sales	402.41	181.38	709.49	340.92	768.14
2	Other Income	0.10	0.06	0.60	0.18	0.36
3	Total Expenses	212.21	123.81	401.79	245.25	520.27
	(a) (Increase)/decrease in Stock in trade	-15.64	10.26	13.55	50.90	38.16
	(b) Trading Purchase	23.84	0.00	28.88	0.00	17.13
	(c) Consumption of raw material	69.43	33.48	137.17	51.18	132.24
	(d) Manufacturing Expenses	33.30	19.69	59.76	38.47	84.71
	(e) Staff Cost	29.74	20.10	54.66	39.56	90.38
	(f) Selling, General & Admn.Expenses	71.54	40.28	107.77	65.14	157.65
4	Interest	5.55	8.54	12.79	15.81	26.33
5	Depreciation.	7.86	6.53	15.11	12.92	26.95
6	Profit (+) /Loss(-) before tax	176.89	42.56	280.40	67.12	194.95
7	Provision for taxation	50.00	5.00	87.50	5.00	87.24
8	Prior Period Expenses	0.00	0.00	0.00	0.00	0.87
9	Net Profit (+) Loss (-)	126.89	37.56	192.90	62.12	106.84
10	Paid-up equity share capital	352.72	352.72	352.72	352.72	352.72
11	Reserve excluding revaluation reserves	-	-	-	-	89.98
12	EPS (Rs.) (not annualised)	3.60	1.06	5.47	1.76	3.03
13	Aggregate of Non promoters					
	- Number of Share	2336650	2332000	2336650	2332000	2336650
	- % of Shareholding	66.25	66.11	66.25	66.11	66.25
Note 1 The Board of Directors have taken on record the aforesaid working results at their meeting held on 27th October,2004 2 During quarter ended 30.09.2004 current tax of Rs. 50.00 lacs is provided, 3 No Investor compliants were pending at the beginning of the quarter. During the quarter one compliant was received which was resolved and so pending complaint at the end of the quarter was nil. 4 Segment wise repoting as definid in Accounting standard (AS) 17 is not aplcable, since the entire operation of the Company relates to only one segment i.e. Poultry Vaccines. 5 The limited review report for the quarter as required under clause 41 of the listing agreement with stock Exchange has been carried out by the Statutory Auditor Place : Ahmedabad Date : 27th October, 2004						
				Rajiv Gandhi Managing Director		